BlackRock Amends NeoGenomics Stake to 9.5% as of Dec 31, 2023
Ticker: NEO · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1077183
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns 9.5% of NEOGENOMICS, signaling continued institutional interest.**
AI Summary
BlackRock Inc. has filed an amended Schedule 13G/A, indicating a change in its ownership stake in NEOGENOMICS INC. As of December 31, 2023, BlackRock Inc. reported beneficial ownership of 12,042,477 shares of NEOGENOMICS INC's Common Stock, representing 9.5% of the company. This is an update to their previous filing and shows BlackRock continues to be a significant institutional holder, which matters to investors as large institutional ownership can signal confidence in the company's long-term prospects.
Why It Matters
This filing shows BlackRock Inc. remains a major institutional investor in NEOGENOMICS INC, holding 9.5% of the common stock, which can be seen as a vote of confidence in the company's future by a prominent asset manager.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
A smart investor would note BlackRock's continued significant stake (9.5%) in NEOGENOMICS INC as of December 31, 2023, which suggests institutional confidence, but should also research any changes in BlackRock's voting power or investment intent, which are not detailed in this specific filing.
Key Numbers
- 12,042,477 — Shares Beneficially Owned (Represents BlackRock Inc.'s total holding in NEOGENOMICS INC as of December 31, 2023.)
- 9.5% — Ownership Percentage (Indicates BlackRock Inc.'s significant stake in NEOGENOMICS INC, showing continued institutional confidence.)
- December 31, 2023 — Reporting Date (The snapshot date for the reported ownership, providing a recent view of BlackRock's position.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- NEOGENOMICS INC (company) — the subject company whose shares are being reported
- 12,042,477 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- 9.5% (dollar_amount) — percentage of NEOGENOMICS INC's class of securities beneficially owned by BlackRock Inc.
- December 31, 2023 (date) — the date of the event which required the filing of this statement
Forward-Looking Statements
- BlackRock Inc. will maintain a significant stake in NEOGENOMICS INC, likely above 5%, for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
- NEOGENOMICS INC's stock price will experience stability or a slight positive sentiment due to continued institutional backing. (NEOGENOMICS INC) — medium confidence, target: June 30, 2024
FAQ
What is the purpose of this SC 13G/A filing by BlackRock Inc. regarding NEOGENOMICS INC?
This SC 13G/A filing is an amendment (Amendment No: 3) to a previous Schedule 13G, indicating an update to BlackRock Inc.'s beneficial ownership of NEOGENOMICS INC's Common Stock as of December 31, 2023.
How many shares of NEOGENOMICS INC Common Stock does BlackRock Inc. beneficially own according to this filing?
BlackRock Inc. beneficially owns 12,042,477 shares of NEOGENOMICS INC Common Stock, as reported in this filing.
What percentage of NEOGENOMICS INC's Common Stock does BlackRock Inc.'s ownership represent?
BlackRock Inc.'s beneficial ownership represents 9.5% of NEOGENOMICS INC's Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement' for this SC 13G/A?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding NEOGENOMICS INC (NEO).